Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Medical Publishing Insights & Practices (MPIP)—a partnership among pharmaceutical companies and the International Society for Medical Publication Professionals—aims to identify ways to improve transparency and credibility in publishing the results of industry sponsored research. This article provides guidance from MPIP on clinically relevant and more informative adverse event reporting, previously identified by journal editors as a significant unmet need to improve patient care and increase the credibility of industry sponsored publications. Our recommendations include highlighting adverse events of most relevance to practitioners and their patients, avoiding broad summary statements such as “generally safe” or “well tolerated,” and including more detailed adverse event data (where appropriate) to offer additional clinically important insight. These recommendations complement the earlier recommendations in the Consolidated Standards of Reporting Trials (CONSORT) Harms Extension. Although developed for industry sponsored trials, the adoption of our recommendations would enhance adverse event reporting in clinical research publications regardless of the funding source and thereby facilitate clinical decision making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Compliance with Results Reporting at ClinicalTrials.gov
Anderson, M. L., Chiswell, K., Peterson, E. D., Tasneem, A., Topping, J., & Califf, R. M. (2015) · New England Journal of Medicine · doi:10.1056/nejmsa1409364 · Cited by 380
Golder, S., Loke, Y. K., Wright, K., & Norman, G. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002127 · Cited by 277
Hodkinson, A., Kirkham, J. J., Tudur-Smith, C., & Gamble, C. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003436 · Cited by 111
Berwaerts, J., Melkote, R., Nuamah, I., & Lim, P. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.047 · Cited by 101
Coulson, M. (2010) · Frontiers in Psychology · doi:10.3389/fpsyg.2010.00026 · Cited by 77 · cited 1×
“29 30 However, for rare events or trials with small sample sizes, it might be more appropriate to list the number of occurrences or individual adverse events without confidence intervals.”
BackgroundSchroll, J. B., Penninga, E. I., & Gøtzsche, P. C. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002101 · Cited by 69 · cited 2×
“45 Therefore, authors should make a reasonable attempt to compare adverse event data in the manuscript to those previously reported from the same trial in publi - cations or conference presentations and other publicly available sources, including submissions to regulatory 19 This adverse event…”
Result
Cited by
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Colombo, N., Sessa, C., Bois, A. D., Ledermann, J., McCluggage, W., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000308 · Cited by 407
Doing no harm in mindfulness-based programs: Conceptual issues and empirical findings
Baer, R., Crane, C., Miller, E., & Kuyken, W. (2019) · Clinical Psychology Review · doi:10.1016/j.cpr.2019.01.001 · Cited by 307
“As defined by the World Health Organization, an AE is an untoward occurrence in a patient or research participant who is administered a pharmaceutical product (Lineberry et al., 2016); an SAE is”
BackgroundDefining and Measuring Meditation-Related Adverse Effects in Mindfulness-Based Programs
Britton, W. B., Lindahl, J. R., Cooper, D. J., Canby, N. K., & Palitsky, R. (2021) · Clinical Psychological Science · doi:10.1177/2167702621996340 · Cited by 278
Junqueira, D. R., Zorzela, L., Golder, S., Loke, Y., Gagnier, J. J., Julious, S. A., Li, T., Mayo-Wilson, E., Pham, B., Phillips, R., et al. (2023) · BMJ · doi:10.1136/bmj-2022-073725 · Cited by 281
Martland, R., Mondelli, V., Gaughran, F., & Stubbs, B. (2020) · Journal of Sports Sciences · doi:10.1080/02640414.2019.1706829 · Cited by 253
Analysis and reporting of adverse events in randomised controlled trials: a review
Phillips, R., Hazell, L., Sauzet, O., & Cornelius, V. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024537 · Cited by 228
CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081124 · Cited by 205
Self-citationSPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials
Hróbjartsson, A., Boutron, I., Hopewell, S., Moher, D., Schulz, K. F., Collins, G. S., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081660 · Cited by 171
Self-citationHarms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events
Mayo-Wilson, E., Fusco, N., Li, T., Hong, H., Canner, J. K., Dickersin, K., Bertizzolo, L., Cowley, T., Doshi, P., Ehmsen, J., et al. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.04.020 · Cited by 109
Citrome, L. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000665 · Cited by 92
Self-citationHarms are assessed inconsistently and reported inadequately part 1: systematic adverse events
Mayo-Wilson, E., Fusco, N., Li, T., Hong, H., Canner, J. K., Dickersin, K., Bertizzolo, L., Cowley, T., Doshi, P., Ehmsen, J., et al. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.04.022 · Cited by 63
Lohmander, F., Lagergren, J., Roy, P. G., Johansson, H., Brandberg, Y., Eriksen, C., & Frisell, J. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003054 · Cited by 73
“Adding to this, the lack of a uniform approach in reporting and standardizing adverse events in surgical trials will further impact interpretation of clinical outcomes.(22) Nevertheless, the high rates of implant loss reported from the Netherlands and by health authorities in France, stand in contrast to data from oth…”
ResultJunqueira, D. R., Zorzela, L., Golder, S., Loke, Y., Gagnier, J. J., Julious, S. A., Li, T., Mayo-Wilson, E., Pham, B., Phillips, R., et al. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.04.005 · Cited by 67
Improving the analysis of adverse event data in randomized controlled trials
Cornelius, V. R., & Phillips, R. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.12.023 · Cited by 27
Van Dam, N. T., Targett, J., Davies, J. N., Burger, A., & Galante, J. (2025) · Clinical Psychological Science · doi:10.1177/21677026241298269 · Cited by 20
“Note that there is no agreed minimal duration that results in an experience being relevant to the individual or treatment or to it potentially being harmful (Lineberry et al., 2016; World Health Organization, 2010).”
Metadata
- Authors
- Lineberry, N., Berlin, J. A., Mansi, B., Glasser, S., Berkwits, M., Klem, C., Bhattacharya, A., Citrome, L., Enck, R., Fletcher, J., Haller, D., Chen, T.-T., & Laine, C.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2016-10-03
- Volume
- 355
- Pages
- i5078
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2528922120
- Cited by
- 113
- References
- 8
- FWCI
- 15.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.